Rami Komrokji, MD | Aplastic Anemia & MDS International Foundation Return to top.

Rami Komrokji, MD

Position / Title: 
Clinical Director, Malignant Hematology Department Lead Clinical Investigator, MDS Program
Institution: 
H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Online Profile: 
https://moffitt.org/research-science/researchers/rami-komrokji/
Primary Disease Area of Focus: 
  • acute myeloid leukemia (AML)
  • aplastic anemia
  • myelodysplastic syndromes (MDS)
  • myeloproliferative neoplasms (MPN)
  • paroxysmal nocturnal hemoglobinuria (PNH)
Practice Location: 
H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Tampa , FL ,
US
Physician Status: 
  • accepting new patients

Other pages on our site that mention Rami Komrokji:

  1. Conference Event - 2022 Seattle, WA, Patient and Family Virtual Conference
  2. Page - Medical Advisory Board
  3. Webinar - Low Risk MDS - AAMDSIF Spring Virtual Conference
  4. Webinar - COVID-19 Update: Focus on Low Risk MDS
  5. Webinar - 8th Seattle Patient Conference - MDS Non Transplant Therapies
  6. Research Article - Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
  7. Conference Event - Aplastic Anemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms: The 8th (Virtual) Patient Conference, June 26, 2021
  8. Research Article - Luspatercept in the treatment of lower-risk myelodysplastic syndromes
  9. Research Article - Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
  10. Research Article - TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  11. Research Article - Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
  12. Research Article - SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes
  13. Research Article - Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
  14. Conference Event - 2020 Patient & Family Spring Virtual Conference
Share with addtoany.com.